Beer TM - Search Results

1

Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients.

Graff JN, Beer TM, Liu B, Sonpavde G, Taioli E. Graff JN, et al. Among authors: beer tm. Clin Genitourin Cancer. 2015 Aug;13(4):e217-e221. doi: 10.1016/j.clgc.2015.01.011. Epub 2015 Jan 30. Clin Genitourin Cancer. 2015. PMID: 25735198

2

Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.

Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, Beer TM, Klein T. Garzotto M, et al. Among authors: beer tm. Cancer. 2003 Oct 1;98(7):1417-22. doi: 10.1002/cncr.11668. Cancer. 2003. PMID: 14508828 Free article.

3

Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.

Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM. Beer TM, et al. Urology. 2004 Feb;63(2):342-7. doi: 10.1016/j.urology.2003.09.045. Urology. 2004. PMID: 14972486

4

Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years.

Beer TM, Berry W, Wersinger EM, Bland LB. Beer TM, et al. Clin Prostate Cancer. 2003 Dec;2(3):167-72. doi: 10.3816/cgc.2003.n.025. Clin Prostate Cancer. 2003. PMID: 15040860 Clinical Trial.

5

Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.

Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M. Janoff DM, et al. Among authors: beer tm. BJU Int. 2005 Sep;96(4):503-7. doi: 10.1111/j.1464-410X.2005.05674.x. BJU Int. 2005. PMID: 16104900

6

The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.

Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG, Crawford ED; Southwest Oncology Group Study. Beer TM, et al. Cancer. 2006 Aug 1;107(3):489-96. doi: 10.1002/cncr.22029. Cancer. 2006. PMID: 16804926 Free article.

7

Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?

Lycette JL, Bland LB, Garzotto M, Beer TM. Lycette JL, et al. Among authors: beer tm. Clin Genitourin Cancer. 2006 Dec;5(3):198-205. doi: 10.3816/CGC.2006.n.037. Clin Genitourin Cancer. 2006. PMID: 17239273 Review.

8

Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.

Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Graff JN, et al. Among authors: beer tm. J Urol. 2007 Apr;177(4):1307-12. doi: 10.1016/j.juro.2006.11.054. J Urol. 2007. PMID: 17382720 Clinical Trial.

9

Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.

Beer TM, Bergenstock M, Birt K, Higano CS. Beer TM, et al. Clin Genitourin Cancer. 2007 Jun;5(5):329-33. doi: 10.3816/CGC.2007.n.012. Clin Genitourin Cancer. 2007. PMID: 17645830

10

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.

Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN; ASCENT Investigators. Beer TM, et al. Cancer. 2008 Jun;112(11):2377-83. doi: 10.1002/cncr.23461. Cancer. 2008. PMID: 18428198 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

310 results

Search Page

Filters